180 Life Sciences Corporate Media Kit

3 • Scientific team and founders are pioneers with proven track record in drug discovery from the University of Oxford, Hebrew University and Stanford University • Developing three families of novel drugs addressing significant market opportunities in inflammation, fibrosis and pain: ─ Fibrosis & Anti-TNF ─ Synthetic CBD Analogs (SCAs) ─ a7nAChR • Multiple programs in synchronized stages of development • Numerous near-term inflection points for anti-TNF programs: one program late stage 2b/3 trial, two additional clinical programs projected to start Q3/4 2021 ─ Initial clinical anti-TNF clinical trials funded by investments and grants (UK). ─ Regulatory approvals obtained from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and the Dutch Centrale Commissie Mensgebonden Onderzoek (CCMO) and the relevant accredited ethics committees to perform clinical trials in the UK and The Netherlands for anti-TNF products(1) • Strong IP portfolio with a long lifespan, providing coverage up to 2039 (1) No meetings have been held with, and no applications or requests for approval have been submitted to the FDA for any products at this time. 180 Life Sciences Highlights 180 Life Sciences Corp. www.180lifesciences.com Q4 2020